IL2 and colorectal carcinoma: A randomised control trial, which compared synbiotic administration to placebo in polypectomised or CRC patients, demonstrated an improvement in several CRC biomarkers, such as DNA damage and cellular proliferation, in the synbiotic group including interleukin-2 and interferon-γ (t3) [115].